Review
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 28, 2025; 31(24): 107661
Published online Jun 28, 2025. doi: 10.3748/wjg.v31.i24.107661
Table 1 Definitions of metabolic syndrome[
22 ,
199 ]
NCEP ATP III (2005)[199 ] IDF (2005)[22 ] Criteria required Three of five criteria below Central obesity required plus two other required criteria Obesity Waist circumference: > 40 inches (101 cm) in men; > 35 inches (88 cm) in women Waist circumference based on ethnicity1 Insulin resistance-serum glucose Fasting serum glucose ≥ 100 mg/dL (≥ 5.6 mmol/L); or medical therapy for hyperglycaemia Fasting serum glucose ≥ 100 mg/dL (≥ 5.6 mmol/L); or medical therapy for hyperglycaemia Dyslipidaemia-serum triglycerides Serum triglyceride level ≥ 150 mg/dL (> 1.7 mmol/L); or medical therapy for dyslipidaemia Triglyceride level ≥ 150 mg/dL (> 1.7 mmol/L); or medical therapy for dyslipidaemia Dyslipidaemia-serum HDL-C Serum HDL-C: < 40 mg/dL (< 1.03 mmol/L) in men; < 50 mg/dL (< 1.29 mmol/L) in women; or medical therapy for dyslipidaemia Serum HDL-C: < 40 mg/dL (< 1.03 mmol/L) in men; < 50 mg/dL (< 1.29 mmol/L) in women; medical therapy for dyslipidaemia Hypertension Systolic blood pressure ≥ 130 mmHg; or diastolic blood pressure ≥ 80 mmHg; or medical therapy for hypertension Systolic blood pressure ≥ 130 mmHg; or diastolic blood pressure ≥ 80 mmHg; or medical therapy for hypertension
Table 2 Observational studies examining prevalence of metabolic disorders in patients with inflammatory bowel disease[
22 ,
32 - 38 ,
40 ,
44 ,
47 ,
49 ,
50 ,
117 ,
118 ,
122 ,
188 ,
195 ,
197 ,
200 - 204 ]
Ref. Country Study type Reference criteria Total number of IBD patients (CD/UC/IBD-U) Prevalence in IBD (%) Prevalence in CD (%) Prevalence in UC (%) Metabolic syndrome Nagahori et al [32 ] Japan Prospective, cross-sectional cohort NCEP-ATP III[188 ] 102 (28/74/-) 18.6 7.1 23.0 Yorulmaz et al [38 ] Turkey Prospective cross-sectional cohort IDF[22 ] 177 (62/115/-) 25.4 17.7 29.5 Sourianarayanane et al [34 ] United States Retrospective cohort NCEP-ATP III[188 ] 217 (110/107/-) 16.6 Fitzmorris et al [200 ] United States Retrospective cohort IDF[22 ] 868 (868/-/-) 4.3 Carr et al [35 ] United States Retrospective cohort NCEP-ATP III[188 ] 84 (60/24/-) 23.0 20.0 29.0 Sartini et al [201 ] Italy Retrospective cohort NCEP-ATP III[188 ] 78 (42/36/-) 23.1 Dragasevic et al [37 ] Serbia Prospective, cross-sectional cohort NCEP-ATP III[188 ] and IDF[22 ] 104 (50/54/-) 32.7 36.0 29.6 Magrì et al [36 ] Italy Prospective cohort NCEP-ATP III[188 ] 178 (83/95/-) 19.1 Jovanovic et al [202 ] Serbia Retrospective cohort NCEP-ATP III[188 ] 89 (-/89/-) 81.0 Kang et al [33 ] Korea Retrospective cohort NCEP-ATP III[188 ] 443 (274/169/-) 10.6 Obesity Long et al [44 ] United States Prospective cross-sectional cohort BMI ≥ 30 kg/m2 1598 (paediatric population) (1027/571/-) 23.6 20.0 30.1 Nic Suibhne et al [50 ] Ireland Prospective case-control study BMI ≥ 30 kg/m2 100 (100/-/-) 17.0 Flores et al [49 ] United States Retrospective cohort BMI ≥ 30 kg/m2 581 (297/284/-) 32.7 30.3 35.2 Seminerio et al [47 ] United States Retrospective cohort BMI ≥ 30 kg/m2 1494 (860/634/-) 31.5 27.0 32.0 Elangovan et al [40 ] United States Retrospective cohort BMI ≥ 30 kg/m2 286, 760 (-/-/-) 37.3 36.9 38.5 Metabolic fatty liver disease Martínez-Domínguez et al [117 ] Spain Prospective cross-sectional cohort MASLD[197 ] 646 (-/-/-) 45.7 Zhang et al [122 ] United Kingdom Prospective cross-sectional cohort MASLD[197 ] 4203 (1217/2642/344) 36.4 Oliveira et al [203 ] Brazil Prospective cross-sectional cohort MASLD[197 ] 140 (89/51/-) 50.7 44.9 43.1 McHenry et al [118 ] United States Prospective cross-sectional cohort NAFLD[195 ] 363 (363/-/-) 39.7 Hyun et al [204 ] Korea Prospective cross-sectional cohort NAFLD[195 ] 3356 (1129/2227/-) 16.7 11.8 19.2 Zhang et al [123 ] United Kingdom Prospective cross-sectional cohort MASLD[197 ] 4622 (1313/2914/-) 38.1
Table 3 Definitions of obesity based on waist circumference in men and women stratified by reference population[
199 ,
205 - 210 ]
Reference population Reference criteria Waist circumference threshold for men Waist circumference threshold for women Europoid IDF[199 ] ≥ 94 cm ≥ 80 cm Caucasian WHO[205 ] ≥ 94 cm = increased risk; ≥ 102 cm = higher risk ≥ 80 cm = increased risk; ≥ 88 cm = higher risk United States of America ATP III[206 ] ≥ 102 cm ≥ 88 cm Canada Health Canada[207 ,208 ] ≥ 102 cm ≥ 88 cm European European Cardiovascular Societies[209 ] ≥ 102 cm ≥ 88 cm Asian IDF[199 ] and WHO[205 ] ≥ 90 cm ≥ 80 cm Japanese Japanese Obesity Society[210 ] ≥ 85 cm ≥ 90 cm China Cooperative Task Force ≥ 85 cm ≥ 90 cm Middle East/Mediterranean IDF[199 ] ≥ 94 cm ≥ 80 cm Sub-Saharan Africa IDF[199 ] ≥ 94 cm ≥ 80 cm Ethnic Central and South American IDF[199 ] ≥ 90 cm ≥ 80 cm
Table 4 Observational studies examining the risk of cardiovascular disorders in patients with inflammatory bowel disease[
16 ,
98 ,
99 ]
Ref. Country Study type Total number of IBD patients (CD/UC/IBD-U) Risk in IBD v s non-IBD HR (95%CI) Risk in CD v s non-IBD HR (95%CI) Risk in UC v s non-IBD HR (95%CI) Ischaemic heart disease Zhu et al [16 ] United Kingdom Prospective cross-sectional cohort 5496 (1861/3635) HR = 0.93 (0.64-1.36) HR = 1.29 (1.03-1.62) Heart failure Aniwan et al [99 ] United States Retrospective cohort 736 (339/397/-) aHR = 2.03 (1.36-3.03) aHR = 1.73 (0.98-3.07) aHR = 2.06 (1.18-3.65) Zhu et al [16 ] United Kingdom Prospective cross-sectional cohort 5496 (1861/3635/-) HR = 1.72 (1.22-2.42) HR = 1.38 (1.07-1.80) Sun et al [98 ] Sweden Prospective cross-sectional cohort 81749 (24303/45709/11737) aHR = 1.19 (1.15-1.23) aHR = 1.28 (1.20-1.36) aHR = 1.14 (1.09-1.19) Ischaemic stroke Zhu et al [16 ] United Kingdom Prospective cross-sectional cohort 5496 (1861/3635/-) HR = 1.32 (0.82-2.12) HR = 1.59 (1.16-2.14)
Table 5 Definitions of metabolic liver diseases[
211 - 213 ]
NAFLD[211 ] MAFLD[212 ] MASLD[213 ] Required criteria Radiological or Histological evidence of hepatic steatosis Cardiometabolic risks required At least 1 of the following 3 criteria required: (1) Obesity: BMI ≥ 25 kg/m2 in Caucasians; or BMI ≥ 23 kg/m2 in Asians; (2) Fasting glucose ≥ 100 mg/dL (≥ 5.6 mmol/L), or on treatment for hyperglycaemia; and (3) Two or more of the following: Elevated waist circumference (Table 2 ); Systolic blood pressure ≥ 130 mmHg; Diastolic blood pressure ≥ 85 mmHg; Serum triglycerides ≥ 150 mg/dL (> 1.7 mmol/L); HDL-C < 40 mg/dL (< 1.03 mmol/L); hsCRP > 2 mg/L; Insulin resistance-HOMA-IR ≥ 2.5; or On treatments for diabetes At least 1 of the following 5 criteria required: (1) Obesity defined by BMI ≥ 25 kg/m2 in Caucasians; or BMI ≥ 23 kg/m2 in Asians; or elevated waist circumference: > 94 cm (males), > 80 cm (females); (2) Fasting glucose ≥ 100 mg/dL (≥ 5.6 mmol/L), or glucose level post glucose tolerance test ≥ 140 mg/dL (7.8 mmol/L), or HbA1c ≥ 5.7% (39 mmol/L) or on treatment for hyperglycaemia; (3) Systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg, or on anti-hypertensive treatment; (4) Serum triglycerides ≥ 150 mg/dL (> 1.7 mmol/L) or on lipid lowering therapy; and (5) HDL-C < 40 mg/dL (< 1.03 mmol/L) in men of < 50 mg/dL (< 1.29 mmol/L) in women or on treatment for dyslipidaemia Additional criteria Other causes of hepatic steatosis excluded